Inovio Pharma (AMEX:INO) has recently announced the publication of the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon vaccine for prostate cancer targeting two antigens. The resultant data showed the induction of strong PSMA-specific cellular immune responses and also significant antigen specific seroconversion, illustrating that both humoral and cellular immune responses can be generated by this approach.

Stock recently rallied by 1.79% to settle at $1.14 with an increased volume of 344,104. Keep an eye on this one as the increase in volume might push the stock for another breakout.

The development of this new treatment for prostate cancer would be a significant medical advance given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and often do not confer long-term cure.

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon(TM) DNA vaccine for prostate cancer targeting two antigens.

NovaBay Pharma (AMEX:NBY) has recently provided a synopsis of its accomplishment as well as the progress from 2010 and its outlook into 2011. NovaBay is in the process of developing commercial opportunities for its Aganocide portfolio of anti-infectives in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections.

Each of these market segments contain indications that are poorly served or have no approved FDA treatments available, with billion-dollar revenue potential. Company's strategy is to address these market opportunities either through partnerships and collaborations or by building an internal organization to strategically market its own products when appropriate from a commercial standpoint.

Shares have gained 5.64% to settle at $0.11 with a moderate volume of 53,654 shares traded by the opening bell.

NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage pharmaceutical company, which is engaged in the discovery and development of synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments.

Plug Power (NASDAQ:PLUG) announced today that the NASDAQ Listing Qualifications Panel has granted the Company's request for continued listing on The NASDAQ Capital Market pursuant to an extension of time to comply with the minimum $1.00 bid price requirement. In accordance with the Panel's decision, before June 6, 2011, the Company must evidence compliance with the bid price requirement for a minimum of ten consecutive business days.

Shares lost 2.97% to settle at $0.65 with an increased volume of 1,675,158 shares traded so far.

Plug Power Inc. is a development-stage company engaged in the design, development and manufacture of fuel cell systems for industrial off-road (forklift or material handling) markets and stationary power markets worldwide. The Company sells and develops a range of fuel cell products and services including hydrogen fuel cell low-temperature proton exchange membrane (PEM) systems for motive and stationary power and a high-temperature fuel cell system for residential and light commercial co-generation.

Chelsea Therapeutics (NASDAQ:CHTP) has reported the results and plans to modify Study 306 to focus on reduction in falls associated with neurogenic orthostatic hypotension. Company announces plans to modify Study 306, a Phase III study of NORTHERA in symptomatic neurogenic orthostatic hypotension associated with Parkinson's disease following a futility determination at the planned interim analysis of the study's primary endpoint. Secondary showed dramatic reduction in falls and clear signs of therapeutic activity associated with Northera in the first 51 patients to complete Study 306.

However with that said, stock took an opposite turn as investors jumped out in panic as the news was perceived pessimistic if they had to modify the study 306. Shares lost 0.54% to settle at $5.02 with a 558,908 shares volume. That significant drop is overdone, there might be an opportunity lingering to make a quick 2-3% in the interim.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.

BPZ Energy (NYSE:BPZ) announced its $50 million 2011 capital expenditures plan for continued development of the Company's assets in northwest Peru. The majority of the capital budget is expected to be spent on offshore Block Z1, primarily for design and construction of an additional production platform for the Corvina oil field; as well as, for injection equipment to be installed on the platform in the Albacora oil field by year-end 2011.

Shares have gained moderately 0.66% to settle at $6.14 with a volume of 1,868,922 shares traded.

BPZ Resources, Inc. is an independent oil and gas company focused on the exploration, development and production of oil and natural gas in Peru and Ecuador. The Company has the exclusive rights and license agreements for oil and gas exploration and production covering approximately 2.2 million acres in four blocks in northwest Peru and off the northwest coast of Peru in the Gulf of Guayaquil. BPZ also owns a 10% non-operated working interest in an oil and gas producing property, Block 2, located in the southwest region of Ecuador.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks.com has not been compensated for any stocks listed in this stock news report

Inovio Pharma (AMEX:INO) has recently announced the publication of the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon vaccine for prostate cancer targeting two antigens. The resultant data showed the induction of strong PSMA-specific cellular immune responses and also significant antigen specific seroconversion, illustrating that both humoral and cellular immune responses can be generated by this approach.

Stock recently rallied by 5.43% to settle at $1.36 with an increased volume of 896,104. Keep an eye on this one as the increase in volume might push the stock for another breakout.

The development of this new treatment for prostate cancer would be a significant medical advance given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and often do not confer long-term cure.

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon(TM) DNA vaccine for prostate cancer targeting two antigens.

NovaBay Pharma (AMEX:NBY) has recently provided a synopsis of its accomplishment as well as the progress from 2010 and its outlook into 2011. NovaBay is in the process of developing commercial opportunities for its Aganocide portfolio of anti-infectives in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections.

Each of these market segments contain indications that are poorly served or have no approved FDA treatments available, with billion-dollar revenue potential. Company's strategy is to address these market opportunities either through partnerships and collaborations or by building an internal organization to strategically market its own products when appropriate from a commercial standpoint.

Shares have droped 0.58% to settle at $1.74 with a moderate volume of 53,654 shares traded by the opening bell.

NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage pharmaceutical company, which is engaged in the discovery and development of synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments.

Plug Power (NASDAQ:PLUG) announced today that the NASDAQ Listing Qualifications Panel has granted the Company's request for continued listing on The NASDAQ Capital Market pursuant to an extension of time to comply with the minimum $1.00 bid price requirement. In accordance with the Panel's decision, before June 6, 2011, the Company must evidence compliance with the bid price requirement for a minimum of ten consecutive business days.

Shares have skyrocketed 11.46% to settle at $0.834 with an increased volume of 1,675,158 shares traded so far.

Plug Power Inc. is a development-stage company engaged in the design, development and manufacture of fuel cell systems for industrial off-road (forklift or material handling) markets and stationary power markets worldwide. The Company sells and develops a range of fuel cell products and services including hydrogen fuel cell low-temperature proton exchange membrane (PEM) systems for motive and stationary power and a high-temperature fuel cell system for residential and light commercial co-generation.

Chelsea Therapeutics (NASDAQ:CHTP) has reported the results and plans to modify Study 306 to focus on reduction in falls associated with neurogenic orthostatic hypotension. Company announces plans to modify Study 306, a Phase III study of NORTHERA in symptomatic neurogenic orthostatic hypotension associated with Parkinson's disease following a futility determination at the planned interim analysis of the study's primary endpoint. Secondary showed dramatic reduction in falls and clear signs of therapeutic activity associated with Northera in the first 51 patients to complete Study 306.

However with that said, stock took an opposite turn as investors jumped out in panic as the news was perceived pessimistic if they had to modify the study 306. Shares plunged 18.77% to settle at $5.02 with a 3,284,908 shares volume. That significant drop is overdone, there might be an opportunity lingering to make a quick 2-3% in the interim.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.

BPZ Energy (NYSE:BPZ) announced its $50 million 2011 capital expenditures plan for continued development of the Company's assets in northwest Peru. The majority of the capital budget is expected to be spent on offshore Block Z1, primarily for design and construction of an additional production platform for the Corvina oil field; as well as, for injection equipment to be installed on the platform in the Albacora oil field by year-end 2011.

Shares have gained moderately 0.66% to settle at $6.14 with a volume of 1,868,922 shares traded.

BPZ Resources, Inc. is an independent oil and gas company focused on the exploration, development and production of oil and natural gas in Peru and Ecuador. The Company has the exclusive rights and license agreements for oil and gas exploration and production covering approximately 2.2 million acres in four blocks in northwest Peru and off the northwest coast of Peru in the Gulf of Guayaquil. BPZ also owns a 10% non-operated working interest in an oil and gas producing property, Block 2, located in the southwest region of Ecuador.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks.com has not been compensated for any stocks listed in this stock news report